On September 8, 2025, Beijing Youngen Biotechnology Co., Ltd. (Youngen) attended the 1st anniversary event of Bayer Co.Lab in China. This "Celebrate for Innovations" themed event aimed to jointly explore the future development potential of China's innovative drugs and drive more breakthrough innovations from China to become solutions for global health challenges. Invited by the event, Professor Hui Zhong, Chief Scientist of Youngen, shared insights over the development and competition landscape of the global small nucleic acid industry, and demonstrated latest achievements of Youngen's cardiac-targeted delivery technology platform as well as its pipelines.
Small nucleic acid drugs lead the third wave of innovative drug development with a strong momentum. They have shown great potentials in the treatment of cardiovascular, metabolism, and rare diseases. However, the extrahepatic delivery still remains a challenge facing the industry. Youngen has successfully broken through the technical bottleneck of extrahepatic delivery with cardiac-targeted delivery technology Kardia-Shuttle™. This small nucleic acids delivery platform is marked by its highly efficient gene knockdown, long acting period and sound safety. Adhering to the concept of "rooted in China, connected to the world" and "open innovation and win-win cooperation", Youngen is committed to in-depth research on fundamental technologies, addressing global needs, and creating infinite possibilities for the future of small nucleic acid drugs through open cooperation.
Beijing Youngen Technology Co., Ltd. is a high-tech biopharmaceutical enterprise dedicated to the R&D and translation of innovative drugs in the field of gene therapy. Focusing on disease mechanism research and innovative drug development, the company has laid out a number of small nucleic acid drug pipelines and extrahepatic drug delivery technology platforms, having achieved breakthrough progress. Based on its transformative delivery technology, Youngen is fully dedicated to the development of small nucleic acid innovative drugs to address the unmet clinical needs, providing precise and efficient treatment solutions for patients worldwide.
Bayer Co.Lab is a pioneering global network of life science incubators focused on disruptive innovation and scientific breakthroughs. With strategic locations around the world, in Berlin, Germany; Cambridge, USA; Kobe, Japan; and Shanghai, China, Bayer Co.Lab connects early-stage entrepreneurs with world-class expertise, resources, and global networks - with no strings attached. Bayer Co.Lab empowers visionary startups by providing state-of-the-art facilities, expert mentorship, and a vibrant community where they can transform groundbreaking ideas into impactful healthcare solutions.
